{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:31:42Z","timestamp":1793151102525,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cellimm.2025.105050","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:41:03Z","timestamp":1762645263000},"page":"105050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Evaluating the impact of using bone marrow-derived macrophages to turn early tumor sites into hot early tumor sites"],"prefix":"10.1016","volume":"418","author":[{"given":"Joshua","family":"Finn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Lass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Oviedo-Bermudez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2025.105050_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.643771","article-title":"Macrophage biology and mechanisms of immune suppression in breast cancer","volume":"12","author":"Mehta","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2025.105050_bb0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-20-3955","article-title":"Randomized phase II study of anti-CSF1 monoclonal antibody lacnotuzumab (MCS110) combined with gemcitabine and carboplatin in advanced triple-negative breast cancer","volume":"28","author":"Kuemmel","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.cellimm.2025.105050_bb0015","doi-asserted-by":"crossref","first-page":"7022","DOI":"10.1158\/0008-5472.CAN-04-1449","article-title":"A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors","volume":"64","author":"Wyckoff","year":"2004","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.cellimm.2025.105050_bb0020","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1158\/0008-5472.CAN-06-1823","article-title":"Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors","volume":"15","author":"Wyckoff","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2025.105050_bb0025","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s12094-021-02652-3","article-title":"Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes","volume":"23","author":"Kuroda","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.cellimm.2025.105050_bb0030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","article-title":"Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy","volume":"44","author":"Imani","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2025.105050_bb0035","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1053\/j.seminoncol.2021.09.002","article-title":"A review of immune checkpoint blockade in breast cancer","volume":"48","author":"Pellegrino","year":"2021","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.cellimm.2025.105050_bb0040","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.cellimm.2025.105050_bb0045","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/(SICI)1096-9896(199702)181:2<200::AID-PATH726>3.0.CO;2-K","article-title":"Angiogenesis and inflammation in ductal carcinoma in situ of the breast","volume":"181","author":"Lee","year":"1997","journal-title":"J. Pathol."},{"key":"10.1016\/j.cellimm.2025.105050_bb0050","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/(SICI)1097-0142(19990825)87:4<203::AID-CNCR7>3.0.CO;2-E","article-title":"Cytologic diagnosis and grading of ductal carcinoma in situ","volume":"87","author":"McKee","year":"1999","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.cellimm.2025.105050_bb0055","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-009-0654-0","article-title":"Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ","volume":"123","author":"Sharma","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.cellimm.2025.105050_bb0060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-016-4036-0","article-title":"Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast","volume":"161","author":"Campbell","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.cellimm.2025.105050_bb0065","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0002-9440(10)63568-7","article-title":"Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases","volume":"163","author":"Lin","year":"2003","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.cellimm.2025.105050_bb0070","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1084\/jem.193.6.727","article-title":"Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy","volume":"193","author":"Lin","year":"2001","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.cellimm.2025.105050_bb0075","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1073\/pnas.0808703105","article-title":"Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation","volume":"106","author":"Wang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.cellimm.2025.105050_bb0080","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26968","article-title":"CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells","volume":"2","author":"Strachan","year":"2013","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.cellimm.2025.105050_bb0085","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1158\/0008-5472.CAN-03-2971","article-title":"Overexpression of the colony-stimulating factor (CSF-1) and\/or its receptor c-fms in mammary glands of transgenic mice results in hyperplasia and tumor formation","volume":"64","author":"Kirma","year":"2004","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.cellimm.2025.105050_bb0090","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.celrep.2019.06.098","article-title":"A spontaneous aggressive ER\u03b1+ mammary tumor model is driven by Kras activation","volume":"28","author":"Campbell","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.cellimm.2025.105050_bb0095","doi-asserted-by":"crossref","first-page":"50731","DOI":"10.18632\/oncotarget.14913","article-title":"Macrophages promote the progression of premalignant mammary lesions to invasive cancer","volume":"8","author":"Carron","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cellimm.2025.105050_bb0100","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.cellimm.2019.103929","article-title":"Analysis of macrophages and neutrophils infiltrating murine mammary carcinoma sites within hours of tumor delivery","volume":"346","author":"Zhang","year":"2019","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.cellimm.2025.105050_bb0105","doi-asserted-by":"crossref","DOI":"10.1080\/08820139.2024.2354264","article-title":"Efficacy of IFN-g, sCD40L, and poly(I:C) treated bone marrow-derived macrophages in murine mammary carcinoma","volume":"53","author":"Roberts","year":"2024","journal-title":"Immunol. Invest."},{"issue":"12","key":"10.1016\/j.cellimm.2025.105050_bb0110","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1248\/bpb.b212024","article-title":"The inhibitory G protein G(i) identified as pertussis toxin-catalyzed ADP-ribosylation","volume":"35","author":"Katada","year":"2012","journal-title":"Biol. Pharm. Bull."},{"issue":"11","key":"10.1016\/j.cellimm.2025.105050_bb0115","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cellimm.2025.105050_bb0120","article-title":"Shaping polarization of tumor-associated macrophages in cancer immunotherapy","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.cellimm.2025.105050_bb0125","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/s41423-023-01013-0","article-title":"The chemokine monocyte chemoattractant protein-1\/CCL2 is a promoter of breast cancer metastasis","volume":"20","author":"Yoshimura","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cellimm.2025.105050_bb0130","first-page":"3282","article-title":"Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer","volume":"6","author":"Ueno","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2025.105050_bb0135","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0165-2478(99)00043-7","article-title":"MCP-1 expression as a potent contributor to the high malignancy phenotype of murine mammary adenocarcinoma cells","volume":"68","author":"Neumark","year":"1999","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.cellimm.2025.105050_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1441820","article-title":"Tumor associated macrophages in breast cancer progression: implications and clinical relevance","volume":"15","author":"Stavrou","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2025.105050_bb0145","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.cellimm.2025.105050_bb0150","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cellimm.2013.01.010","article-title":"Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin","volume":"281","author":"Jaguin","year":"2013","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.cellimm.2025.105050_bb0155","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3389\/fimmu.2017.01383","article-title":"Toll-like receptor ligands and interferon-\u03b3 synergize for induction of antitumor M1 macrophages","volume":"8","author":"M\u00fcller","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2025.105050_bb0160","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev.immunol.16.1.111","article-title":"CD40 and CD154 in cell-mediated immunity","volume":"16","author":"Grewal","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2025.105050_bb0165","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.cellimm.2025.105050_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2013.01.004","article-title":"The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy","volume":"25","author":"Moran","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.cellimm.2025.105050_bb0175","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/intimm\/14.3.275","article-title":"Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells","volume":"14","author":"Futagawa","year":"2002","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cellimm.2025.105050_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1160116","article-title":"The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy","volume":"14","author":"Frankish","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.cellimm.2025.105050_bb0185","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41590-023-01430-3","article-title":"CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions","volume":"24","author":"Liu","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cellimm.2025.105050_bb0190","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/eji.201847888","article-title":"Poly(I:C) stimulation is superior than imiquimod to induce the antitumoral functional profile of tumor-conditioned macrophages","volume":"49","author":"Maeda","year":"2019","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.cellimm.2025.105050_bb0195","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1073\/pnas.1113099109","article-title":"Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors","volume":"109","author":"Shime","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.cellimm.2025.105050_bb0200","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3390\/pharmaceutics13020142","article-title":"TLR agonists as vaccine adjuvants targeting cancer and infectious diseases","volume":"13","author":"Luchner","year":"2021","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.cellimm.2025.105050_bb0205","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010237","article-title":"Flagellin engineering enhances CAR-T cell function by reshaping tumor microenvironment in solid tumors","volume":"13","author":"Niu","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.cellimm.2025.105050_bb0210","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/icb.2014.74","article-title":"Anti-metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10","volume":"93","author":"de Melo","year":"2015","journal-title":"Immunol. Cell Biol."},{"issue":"2","key":"10.1016\/j.cellimm.2025.105050_bb0215","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.imlet.2009.06.007","article-title":"TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses","volume":"125","author":"Vicente-Suarez","year":"2009","journal-title":"Immunol. Lett."},{"issue":"376","key":"10.1016\/j.cellimm.2025.105050_bb0220","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aak9537","article-title":"Two-step enhanced cancer immunotherapy with engineered salmonella typhimurium secreting heterologous flagellin","volume":"9","author":"Zheng","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.cellimm.2025.105050_bb0225","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","article-title":"TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy","volume":"2","author":"Rodell","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.cellimm.2025.105050_bb0230","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.actbio.2020.09.038","article-title":"Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy","volume":"133","author":"Figueiredo","year":"2021","journal-title":"Acta Biomater."},{"issue":"3","key":"10.1016\/j.cellimm.2025.105050_bb0235","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.3892\/mmr.2015.3885","article-title":"Toll-like receptor 7\/8 agonist, R848, exhibits antitumoral effects in a breast cancer model","volume":"12","author":"Yin","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.cellimm.2025.105050_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1351655","article-title":"CCR5\/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome","volume":"15","author":"Chernov","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.cellimm.2025.105050_bb0245","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.4049\/jimmunol.2300431","article-title":"Single-cell analysis reveals a subset of high IL-12p40-secreting dendritic cells within mouse bone marrow-derived macrophages differentiated with M-CSF","volume":"212","author":"Bridges","year":"2024","journal-title":"J. Immunol."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874925001364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874925001364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:14:32Z","timestamp":1763644472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874925001364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":49,"alternative-id":["S0008874925001364"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2025.105050","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the impact of using bone marrow-derived macrophages to turn early tumor sites into hot early tumor sites","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2025.105050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105050"}}